Midu (米度) is a CRDMO that leverages nuclear‑medicine technologies to provide R&D outsourcing services to domestic and international pharmaceutical clients. The company operates in Yantai, Nanjing, Wuxi and Guangzhou and offers preclinical and clinical molecular imaging, radiolabeling, and PK/PD studies across small molecules, peptides, antibodies, cell therapies and other modalities. Midu has AAALAC‑accredited radioactive laboratories, qualifications for 26 radionuclides, and both clinical and animal PET/CT capability enabling continuous dynamic and static scans. It provides end‑to‑end nuclear‑drug CRDMO services from early screening through clinical development and registration, and has assisted more than 20 radiopharmaceutical products in obtaining clinical trial approvals. In non‑nuclear areas the firm acts as a molecular‑imaging CRO with strong radiotracer production and image analysis capabilities recognized by global pharma customers. CEO Gilles Tamagnan has stated the company intends to build integrated domestic translational platforms and overseas imaging centers to accelerate clinical translation and international registrations.

Total raised

$56M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2024